Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Sutro Biopharma Inc (STRO)
NASDAQ:STRO
STRO Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.51 - $6.13
Previous CloseN/A
Volume326.60K
Average Volume (3M)937.15K
Market Cap
$154.20M
Enterprise Value$92.45M
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta2.83
Next Earnings
Mar 26, 2025EPS Estimate
-0.83Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.62
Shares Outstanding82,458,725
10 Day Avg. Volume1,077,491
30 Day Avg. Volume937,151
Standard Deviation0.20
R-Squared0.09
Alpha-0.02
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)0.96
Price to Cash Flow (P/CF)-0.60
P/FCF Ratio0.00
Enterprise Value/Market Cap0.60
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit0.63
Enterprise Value/Ebitda-1.12
Forecast
1Y Price Target
$10.75Price Target Upside487.43% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
---
Sutro Biopharma News
PremiumCompany Announcements
Sutro Biopharma Advances Pipeline Amid Financial Losses
---
Bulls Say, Bears Say
Bulls Say
Clinical TrialsThe pivotal REFRαME-O1 trial is progressing with a goal to have numerous active sites across multiple countries, aiming for potential accelerated approval.
Financial PositionSutro Biopharma's solid cash position of $388.3MM and multiple partners providing non-dilutive capital highlight its financial stability.
PartnershipsSutro Biopharma's ongoing partnership discussions and solid cash position present a unique investment opportunity.
Bears Say
Efficacy ConcernsThe efficacy of Luvelta seems more modest if consistent across FolRa expression levels, raising concerns about its performance.
Launch DelaysThe potential launch timing for Luvelta seems to be pushed to 2028, which may be contributing to weaker share performance.
Market SentimentThe stock is likely down due to mid-2027 timing for a BLA filing in PROC being a push relative to consensus.
---
Ownership Overview
8.82% Insiders
10.67% Mutual Funds
34.45% Other Institutional Investors
35.41% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
STRO FAQ
What was Sutro Biopharma Inc’s price range in the past 12 months?
Sutro Biopharma Inc lowest stock price was $1.51 and its highest was $6.13 in the past 12 months.
What is Sutro Biopharma Inc’s market cap?
Sutro Biopharma Inc’s market cap is $154.20M.
When is Sutro Biopharma Inc’s upcoming earnings report date?
Sutro Biopharma Inc’s upcoming earnings report date is Mar 26, 2025 which is in 32 days.
How were Sutro Biopharma Inc’s earnings last quarter?
Sutro Biopharma Inc released its earnings results on Nov 13, 2024. The company reported -$0.59 earnings per share for the quarter, beating the consensus estimate of -$0.735 by $0.145.
Is Sutro Biopharma Inc overvalued?
According to Wall Street analysts Sutro Biopharma Inc’s price is currently Undervalued.
Does Sutro Biopharma Inc pay dividends?
Sutro Biopharma Inc does not currently pay dividends.
What is Sutro Biopharma Inc’s EPS estimate?
Sutro Biopharma Inc’s EPS estimate is -0.83.
How many shares outstanding does Sutro Biopharma Inc have?
Sutro Biopharma Inc has 82,458,725 shares outstanding.
What happened to Sutro Biopharma Inc’s price movement after its last earnings report?
Sutro Biopharma Inc reported an EPS of -$0.59 in its last earnings report, beating expectations of -$0.735. Following the earnings report the stock price went down -12.879%.
Which hedge fund is a major shareholder of Sutro Biopharma Inc?
Currently, no hedge funds are holding shares in STRO
---
Sutro Biopharma Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$10.75 (487.43% Upside)
$10.75 (487.43% Upside)
Blogger Sentiment
Bullish
STRO Sentiment 100%
Sector Average 71%
Sector Average 71%
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.9%
Last 30 Days ▼ 1.1%
Last 30 Days ▼ 1.1%
News Sentiment
Very Bullish
Bullish news 99%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-61.14%
12-Months-Change
Fundamentals
Return on Equity
-110.89%
Trailing 12-Months
Asset Growth
4.66%
Trailing 12-Months
Company Description
Sutro Biopharma Inc
Sutro Biopharma Inc. engages in the drug discovery, development and manufacturing of pharmaceutical products. Its products technologies include XpressCF, anti-body drug conjugates, bispecifics & engineered antibodies and cGMP facility. The company was founded by James R. Swartz and Sutanto Widjaja in June 2003 and is headquartered in South San Francisco, CA.
---
STRO Stock 12 Month Forecast
Average Price Target
$10.75
▲(487.43% Upside)
Technical Analysis
Best Analysts Covering STRO
1 Year
1 Year Success Rate
8/34 ratings generated profit
1 Year Average Return
-27.02%
reiterated a buy rating last month
Copying Reni Benjamin's trades and holding each position for 1 Year would result in 23.53% of your transactions generating a profit, with an average return of -27.02% per trade.
---